Emergent BioSolutions Inc. (NYSE:EBS) Shares Acquired by LPL Financial LLC

LPL Financial LLC increased its stake in shares of Emergent BioSolutions Inc. (NYSE:EBS) by 34.5% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 15,120 shares of the biopharmaceutical company’s stock after acquiring an additional 3,875 shares during the quarter. LPL Financial LLC’s holdings in Emergent BioSolutions were worth $145,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently bought and sold shares of EBS. American Century Companies Inc. increased its position in shares of Emergent BioSolutions by 23.4% during the fourth quarter. American Century Companies Inc. now owns 2,137,712 shares of the biopharmaceutical company’s stock worth $20,437,000 after purchasing an additional 404,667 shares in the last quarter. Connor Clark & Lunn Investment Management Ltd. lifted its stake in Emergent BioSolutions by 8.3% in the fourth quarter. Connor Clark & Lunn Investment Management Ltd. now owns 902,332 shares of the biopharmaceutical company’s stock valued at $8,626,000 after buying an additional 69,157 shares during the last quarter. Prescott Group Capital Management L.L.C. boosted its holdings in shares of Emergent BioSolutions by 250.0% in the fourth quarter. Prescott Group Capital Management L.L.C. now owns 210,000 shares of the biopharmaceutical company’s stock valued at $2,008,000 after acquiring an additional 150,000 shares during the period. E Fund Management Co. Ltd. purchased a new position in shares of Emergent BioSolutions during the fourth quarter worth approximately $98,000. Finally, SBI Securities Co. Ltd. purchased a new stake in Emergent BioSolutions in the 4th quarter valued at $63,000. 78.40% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently weighed in on the stock. HC Wainwright reiterated a “buy” rating and set a $15.00 target price on shares of Emergent BioSolutions in a research note on Tuesday, April 1st. StockNews.com downgraded shares of Emergent BioSolutions from a “buy” rating to a “hold” rating in a report on Wednesday, March 5th.

Insider Transactions at Emergent BioSolutions

In other Emergent BioSolutions news, Director Neal Franklin Fowler sold 35,000 shares of the stock in a transaction on Wednesday, March 12th. The stock was sold at an average price of $5.83, for a total transaction of $204,050.00. Following the sale, the director now owns 101,100 shares in the company, valued at approximately $589,413. This represents a 25.72 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Corporate insiders own 1.20% of the company’s stock.

Emergent BioSolutions Stock Down 2.2 %

EBS opened at $5.33 on Thursday. Emergent BioSolutions Inc. has a one year low of $1.87 and a one year high of $15.10. The company has a market cap of $289.62 million, a price-to-earnings ratio of -1.30 and a beta of 2.14. The business’s fifty day moving average is $5.39 and its two-hundred day moving average is $8.11. The company has a debt-to-equity ratio of 1.30, a quick ratio of 1.47 and a current ratio of 2.88.

Emergent BioSolutions (NYSE:EBS) last issued its quarterly earnings data on Monday, March 3rd. The biopharmaceutical company reported $0.05 EPS for the quarter, beating analysts’ consensus estimates of ($0.35) by $0.40. The firm had revenue of $194.70 million for the quarter, compared to analysts’ expectations of $254.67 million. Emergent BioSolutions had a negative net margin of 18.55% and a negative return on equity of 9.91%. During the same period in the prior year, the company earned ($0.77) EPS. Analysts anticipate that Emergent BioSolutions Inc. will post -0.63 EPS for the current fiscal year.

Emergent BioSolutions announced that its board has approved a share repurchase plan on Monday, March 31st that authorizes the company to buyback $50.00 million in outstanding shares. This buyback authorization authorizes the biopharmaceutical company to buy up to 19% of its shares through open market purchases. Shares buyback plans are typically an indication that the company’s leadership believes its shares are undervalued.

Emergent BioSolutions Profile

Emergent BioSolutions Inc, a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax.